Cost-effectiveness of Interferon-γ Release Assay Screening for Latent Tuberculosis Infection Treatment in Germany

OBJECTIVES To assess the cost-effectiveness of the new QuantiFERON-TB Gold In-Tube (QFT-G) [Cellestis; Carnegie, VIC, Australia] assay for screening and treating of persons who have had close contact with tuberculosis (TB) patients and are suspected of having latent tuberculosis infection (LTBI) [hereafter called close-contacts] in Germany. METHODS The health and economic outcomes of isoniazid treatment of 20-year-old close-contacts were compared in a Markov model over a period of 20 years, using two different cutoff values for the tuberculin skin test (TST), the QFT-G assay alone, or the QFT-G assay as a confirmatory test for the TST results. RESULTS QFT-G assay-based treatment led to cost savings of $542.9 and 3.8 life-days gained per LTBI case. TST-based treatment at a 10-mm induration size cutoff gained $177.4 and 2.0 life-days gained per test-positive contact. When the cutoff induration size for the TST was reduced to 5 mm, the incremental cost-effectiveness ratio fell below the willingness-to-pay threshold ($30,170 per life-years gained) but resulted in unnecessary treatment of 77% of contacts owing to false-positive TST results. Combination with the 5-mm induration size TST cutoff value compared to the results of the QFT-G assay alone reduced the total costs per 1,000 contacts by 1.8% to $222,869. The number treated to prevent 1 TB case was 22 for the two QFT-G assay-based procedures, 40 for the TST at a cutoff induration size of 10 mm, and 96 for the TST at a cutoff induration size of 5 mm. When the sensitivity rates of the TST and the QFT-G assay were compounded, the QFT-G assay strategy alone was slightly less costly (0.6%) than the two-step approach. CONCLUSIONS Using the QFT-G assay, but especially combining the QFT-G assay following the TST screening of close-contacts at a cutoff induration size of 5 mm before LTBI treatment is highly cost-effective in reducing the disease burden of TB.

[1]  S. Niemann,et al.  Avoiding the effect of BCG vaccination in detecting Mycobacterium tuberculosis infection with a blood test , 2006, European Respiratory Journal.

[2]  T. Shim,et al.  Comparison of two commercial interferon-γ assays for diagnosing Mycobacterium tuberculosis infection , 2006, European Respiratory Journal.

[3]  D. Cirillo,et al.  Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients , 2006, European Respiratory Journal.

[4]  R. Diel,et al.  Cost-optimisation of screening for latent tuberculosis in close contacts , 2006, European Respiratory Journal.

[5]  P. Wrighton-Smith,et al.  Direct costs of three models for the screening of latent tuberculosis infection , 2006, European Respiratory Journal.

[6]  Bryan Lewis,et al.  Cost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants , 2006, BMC public health.

[7]  R. Diel,et al.  Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons , 2006, Respiratory research.

[8]  J. Zellweger,et al.  Contact tracing using a new T-cell-based test: better correlation with tuberculosis exposure than the tuberculin skin test. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[9]  R. Diel,et al.  Cost-effectiveness of isoniazid chemoprevention in close contacts , 2005, European Respiratory Journal.

[10]  D. Menzies,et al.  Cost-effectiveness of tuberculosis control strategies among immigrants and refugees , 2005, European Respiratory Journal.

[11]  P. Francioli,et al.  Influence of bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction: to what size? , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Y. Sasaki,et al.  Specific Detection of Tuberculosis Infection: An Interferon-γ–based Assay Using New Antigens , 2004 .

[13]  R. Horsburgh,et al.  Priorities for the treatment of latent tuberculosis infection in the United States. , 2004, The New England journal of medicine.

[14]  D. Sagebiel,et al.  Latente tuberkulöse Infektion: Empfehlungen zur präventiven Therapie bei Erwachsenen in Deutschland , 2004 .

[15]  W. Haas,et al.  [Recommendations for personal respiratory protection in tuberculosis]. , 2004, Pneumologie.

[16]  J. Deeks,et al.  Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak , 2003, The Lancet.

[17]  K. Dasgupta,et al.  Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations. , 2000, American journal of respiratory and critical care medicine.

[18]  D. Chin,et al.  Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness. , 1999, American journal of respiratory and critical care medicine.

[19]  S. Buskin,et al.  Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. , 1999, JAMA.

[20]  M. Behr,et al.  Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli , 1999, The Lancet.

[21]  D K Owens,et al.  Interpretation of cost-effectiveness analyses , 1998, Journal of general internal medicine.

[22]  E. Salpeter,et al.  Mathematical model for the epidemiology of tuberculosis, with estimates of the reproductive number and infection-delay function. , 1998, American journal of epidemiology.

[23]  R. Ferlinz.  [Guidelines for environmental contact tracing in tuberculosis. German Central Committee for control of tuberculosis]. , 1996, Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)).

[24]  M. Weinstein,et al.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.